Navigation Links
Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter

BRUSSELS, Belgium and GENEVA, Sept. 3 /PRNewswire/ -- Artelis SA and Selexis SA announced today a new milestone in CHO based monoclonal antibody production with the achievement of manufacturing yields of over 31 grams per liter. This record level was accomplished by applying two highly innovative technologies: (1) a high-performance stable Selexis CHO production cell line rapidly generated by industry leading scientists at Selexis SA using their proprietary Selexis Genetic Elements(TM) and (2) the application of iCELLis(TM) scalable, disposable, high-cell-density technology developed by the innovative scientists at Artelis.

The full program was concluded over about 4 months, starting with the development of a high-performance cell line development at Selexis, followed by cell transfer and manufacturing at Artelis. The culture media used throughout the study was industry standard cGMP grade and void of serum or any animal derived components.

Dr. Igor Fisch, Co-founder and CEO of Selexis commented on the achievements:

"The productivity and stability of the Selexis high-performance cell lines are a perfect fit for the iCELLis(TM) technology, which has the ability to reach incredibly high-cell-densities of up to 250 mio cells per ml". "The usefulness and potential applications of the combined approach could stretch across the biotech industry, beyond just large scale bioproduction".

Dr. Jose Castillo, Co-founder and President of Artelis commented on the achievements:

"These results show the power of the iCELLis(TM) technology. When combined with a high-performance cell line, like one from Selexis', we have the opportunity to reach ultra high productivity levels." "We firmly believe the iCELLis(TM) system will change the approach companies take for the small and large scale production of recombinant proteins."

Further details on this milestone achievement will be presented at the upcoming Bioprocess International Conference being held in Anaheim, California, September 23 -- 26, 2008.

Artelis and Selexis plan to expand the testing of the combined technologies by evaluating the iCELLis(TM) platform with Selexis generated HEK293 cells lines.

About the Artelis iCELLis(TM) Technology:

iCELLis (TM) is a proprietary, single-use, technology developed by Artelis. iCELLis(TM) is designed to achieve and maintain high-cell densities on macrocarriers in a fixed-bed system. Achieving high-cell densities allows compact iCELLis(TM) bioreactors to equal the productivity of much larger stirred-tank units. Depending on cell type and process, iCELLis(TM) can achieve 20-100x the volumetric productivity of a stirred-tank bioreactor.

iCELLis(TM) represents the next generation of disposable bioreactor technology, enabling process intensification in upstream processing by reducing bioreactor scale and simplifying operations.

About Artelis:

Artelis is an international and innovative SME founded in 2005. Capitalised by an American company listed on NASDAQ, Artelis is the privileged partner of world-leading pharmaceutical groups. The company has broad experience with disposable technologies: Artelis developed the Newmix(R) Jet Drive(TM), disposable mixing system, and co-developed the Nucleo(TM) disposable bioreactor together with ATMI Lifesciences and Pierre Guerin Biolafitte. Artelis is concerned by the process intensification needs in the biotech industry and dedicated to process development in disposable technologies. Artelis' mission is to create the future means of producing proteins, cells and viruses for key markets: monoclonal antibodies, cell therapy, vaccines and gene therapy. For more information, please visit

About the Selexis Genetic Elements(TM):

Selexis Genetic Elements (TM) are applied to control the dynamic organization of transgenes in the chromatin of eukaryotic production cells. The Selexis Genetic Elements(TM) enable the creation of loops of open chromatin upon the stable integration of the SGE containing vectors. Selexis Genetic Elements(TM) based vectors have been shown to significantly increase the population of independently transformed cells stably expressing the gene of interest at very high levels. Selexis Genetic Elements(TM) are available for out-license.

About Selexis SURE Cell Line Development(SM) Program: The Selexis SURE Cell Line Development(SM) program is a novel cell line development procedure designed to maximize the effectiveness of the Selexis technology. Using the Selexis SURE Cell Line Development program, Selexis scientists can generate high-performance stable minipools in as little as 5 week following transfection or high-performance clonal cell lines 12 weeks after transfection. Like the Selexis Genetic Elements(TM) the Selexis SURE Cell Line Development Program is available for out-license.

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services to speed the development of high performance mammalian cell lines. The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development(SM) process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.

For more information visit Selexis at

Selexis Genetic Elements(TM) and SURE Cell Line Development(SM) are trademarks of Selexis SA.

iCELLis(TM) is a trademark of Artelis SA.

SOURCE Selexis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
2. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
3. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
4. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
7. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
8. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
9. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
Post Your Comments:
(Date:11/24/2015)... BOULDER, Colo. , Nov. 24, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The public ... a webcast on the Array BioPharma website.Event:Piper Jaffray ... OfficerDate:  , Wednesday, December 2, 2015Time:1:30 p.m. Eastern ...
(Date:11/24/2015)... , Nov. 24, 2015  DILON Diagnostics and GE ... an agreement for DILON to distribute GE,s Discovery NM750b ... globe. The signing of this distribution agreement will provide Dilon,s ... Breast Imaging system and is considered an initial step ... healthcare solutions for clinicians and their patients. ...
(Date:11/24/2015)... . --> ... Latest Guidebook for Chinese Medical Device GMP Regulations ... November 2015 to the medical devices market data ... . China ... economies with a fifth population in the world, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... specializing in both surgical and non-surgical treatments, announced the expansion of his private ... Plastic Surgery. , Highly trained and nationally recognized for his natural approach, ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... ... 25, 2015 , ... Castlewood Treatment Center for Eating Disorders, ... as a result of the $20,000 raised at the center’s recent golf ... Club in Eureka, will help individuals who otherwise might not seek treatment for ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... that it has undertaken significant expansion of its current state of the art ... part of PharmaTech’s strategy to increase its manufacturing capacity as well as to ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a ... (TSC), as well as raising public awareness of the disorder while helping to ... third donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center ...
Breaking Medicine News(10 mins):